New medicines recommended for approval by EMA's CHMP in March
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five medicines for approval at its March 2022 meeting. A final decision on approval is announced by the European Commission, which usually take around two-to-three months.
These included AstraZeneca’s (LSE: AZN) monoclonal antibody Evusheld (tixagevimab/cilgavimab) received a positive opinion from the CHMP for the prevention of COVID-19. Details of this are covered in a separate article.
A new gene therapy, Carvykti (ciltacabtagene autoleucel), from Johnson & Johnson’s (NYSE: JNJ) subsidiary Janssen-Cilag, received a positive opinion for a conditional marketing authorization for the treatment of multiple myeloma. Carvykti had support through the PRIME scheme, the EMA’s platform for early and enhanced dialogue with developers of promising new medicines that address unmet medical needs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze